Business
Neurochem announces departure of Dr. Philippe Calais, President, Global Business
LAVAL, QC, Nov. 30 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announces the dep...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nLAVAL, QC, Nov. 30 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)\ntoday announces the departure of Philippe Calais, PhD. Pharm., Neurochem's\nPresident, Global Business. Dr. Calais joined Neurochem in 2003, and is\nleaving effective December 31, 2007, to pursue other interests.\n\n\n"Dr. Calais has made a significant contribution to creating constructive\nrelationships for Neurochem in international markets and we are grateful for\nhaving had the benefit of his expertise during the five years he has been with\nus," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO. "We\nwish him every success in his new pursuits."\n\n\nAbout Neurochem\n\n\nNeurochem Inc. is a global health company focused on the research,\ndevelopment and commercialization of products to provide innovative health\nsolutions to patients suffering from serious diseases.\n\n\nTo Contact Neurochem\n\n\nFor additional information on Neurochem and its drug development\nprograms, please call the North American toll-free number 1 877 680-4500 or\nvisit the Web Site at: www.neurochem.com.\n\n\nCertain statements contained in this news release, other than statements\nof fact that are independently verifiable at the date hereof, may constitute\nforward-looking statements. Such statements, based as they are on the current\nexpectations of management, inherently involve numerous risks and\nuncertainties, known and unknown, many of which are beyond Neurochem's\ncontrol. Such risks include but are not limited to: the impact of general\neconomic conditions, general conditions in the pharmaceutical and/or\nnutraceutical industry, changes in the regulatory environment in the\njurisdictions in which Neurochem does business, stock market volatility,\nfluctuations in costs, and changes to the competitive environment due to\nconsolidation, that actual results may vary once the final and\nquality-controlled verification of data and analyses has been completed, as\nwell as other risks disclosed in public filings of Neurochem. Consequently,\nactual future results may differ materially from the anticipated results\nexpressed in the forward-looking statements. The reader should not place undue\nreliance, if any, on the forward-looking statements included in this news\nrelease. These statements speak only as of the date made and Neuroc...